Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 7Unknown 5Recruiting 3Completed 3Not yet recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Stomach Neoplasms 7Rectal Neoplasms 5Nasopharyngeal Carcinoma 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Pancreatic Neoplasms 3Melanoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Advanced Solid Tumor 2Triple Negative Breast Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms by Site 1

Interventions

Bevacizumab 47lenvatinib 36atezolizumab 36durvalumab 28tremelimumab 23sintilimab 19Nivolumab 18pembrolizumab 14Radiosurgery 13tislelizumab 11Specimen Handling 10Ipilimumab 10camrelizumab 8apatinib 8Oxaliplatin 8Immune Checkpoint Inhibitors 8Fluorouracil 8Cyclophosphamide 8Blood Specimen Collection 8regorafenib 7cabozantinib 7fludarabine 6Sorafenib 6Radiotherapy 6Magnetic Resonance Spectroscopy 6Leucovorin 6donafenib 5Surgical Procedures, Operative 5Injections 5Immunoglobulin G 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Hepatocellular × spartalizumab × Clear all
NCT05713994 2025-03-25

CCGLC-001

Tongji Hospital

Recruiting
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06349044 2024-08-27

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Zhejiang Cancer Hospital

Phase NA Recruiting
120 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05717738 2024-06-13

CCGLC-008

Tongji Hospital

Recruiting
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡